Blood pressure drug could be used as dementia treatment

Tests are being carried out on what could be the first ever treatment for dementia - a development which could change the lives of hundreds of thousands of people.

Tests are being carried out on what could be the first ever treatment for dementia – a development which could change the lives of hundreds of thousands of people.

It is thought that the treatment could be provided by amlodipine: a drug which is widely prescribed for high blood pressure and which costs just four pence a day.

Nearly 600 people are scheduled to take part in what will be a major study; half will be given a dummy pill and all participants will have their brains scanned at the beginning and one year after the trial. The participants will also have their memories tested at certain points.

It is thought that a reduction in blood pressure could aid blood flow to the brain, helping to improve both memory and cognition.

Should the trials prove successful, it could result in amlodipine being used as a treatment for vascular dementia in nursing homes within five or ten years’ time.

Image Credit: Aletia (Shutterstock.com)

Cookie Settings

Carebase understands that your information is important and in the wrong hands it poses a risk to your rights and freedoms. In order to help you protect your information our Privacy Policy will explain what information we collect, why we collect it, what we do with it, how long we keep it for, who can access it and what your rights are.

Read our Privacy Policy.

Necessary Cookies

Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

Statistics & Marketing

Statistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.

Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.